Why the study?
Consensus on the clinical significance and management of Lambl's excrescences remains sparse despite numerous case reports and observational studies.
Does a novel oral anticoagulant prevent recurrent embolic stroke in a patient with Lambl's excrescences?
Does a novel oral anticoagulant prevent recurrent embolic stroke in a patient with Lambl's excrescences?
Anticoagulation with a novel oral anticoagulant successfully prevented recurrent embolic stroke at 3 months in a patient with a 1-mm aortic valve Lambl's excrescence.
Answers are grounded in this paper and cite their sources.
May link Lambl's excrescences to recurrent strokes; leaves open their significance and management.
Lambl's excrescences were first described in 1856 by a Bohemian physician, Vilém Dušan Lambl, and since then have gained widespread attention and controversy within the medical literature. Despite numerous case reports and observational studies, consensus on the significance and management of Lambl's excrescences remains sparse. We describe the case of a 48-year-old male who presented with recurrent embolic strokes. No underlying paroxysmal arrhythmia or inter-atrial shunt was identified, and the only pathological finding was a 1-mm aortic valve strand. We managed this patient successfully using a novel oral anticoagulant.
No takes yet. Share an insight, caveat, or question.
Amin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: